Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT00265174
Other study ID # IRISL1-HMO-CTIL
Secondary ID
Status Not yet recruiting
Phase N/A
First received December 13, 2005
Last updated December 13, 2005
Start date January 2006

Study information

Verified date November 2005
Source Hadassah Medical Organization
Contact ARIK TZUKERT, DMD
Phone 00-972-2-6776095
Email ARIK@HADASSAH.ORG.IL
Is FDA regulated No
Health authority Israel: Israeli Health Ministry Pharmaceutical Administration
Study type Observational

Clinical Trial Summary

Numerous studies document the ability of tumors to shed DNA into the blood stream. Circulating DNA can thus be recovered for analyses, representing a surrogate tumor material to test for potential applications in disease diagnosis and prognosis.

Detection of genetic alternation is one of the most important tests for cancer patient since they offen correlated with the clinical course, prognosis and chemosensitivity of primary brain tumors. Currently in brain tumor patients these molecular aberrations can be analyzed only on tumor tissue that was obtained at surgery or biopsy.

Paucity of pathologic samples or poor fixation technique often make the tissue samples unassessable for molecular aberrations.

Therefore, the ability to extract tumor DNA from peripheral blood holds a great clinical significance. Still, the molecular aberration evaluated on serum DNA should be correlated and verified by comparison to standard evaluations performed on tumor samples. Our study aim is to evaluate the feasibility of using serum DNA for routine diagnosis of tumor molecular aberrations.


Description:

Backround:

Genetic and epigenetic abrasions like loss of hetherozygosity and hypermethylation of gene promoters are common aberration in gliomas. Detection of these aberrations serves as diagnostic and prognostic tool. Examples: 1. oligodendrogliomas patients with combined 1p/19q LOH within the tumor respond better to chemotherapy and have better prognosis, whereas LOH on chromosome 10q is a marker for worse prognosis. 2. GBM patients with hypermethylation of the promoter of methyl-guanine-methyl-transferase (MGMT) in the tumor respond better to alkylating agent and have better prognosis.

As sample materials for diagnosis should be easily accessible by a minimally invasive procedure, there has been much interest in the potential use of nucleic acid markers in the blood of patients with cancer.

It was demonstrated that LOH as well as hypermethylation could be detected in the plasma/serum of patients with a variety of malignancies, suggesting that circulating tumor-associated DNA in the blood of patients can be a key determinant in predicting genetic and epigenetic abrasions in the tumor.

Objectives of the study:

Main objective: to find whether genetic abrasions in serum DNA represent the tumor DNA in patients with brain tumor.

Is tumor DNA can be detected in the serum of only high grade tumors or also in low grade tumor?

Methods:

Blood serum and tumor of patients are obtained anonymously, after the patient has signed a consent form, prior to surgery as part of the procedure for tissue collection for the brain tumor bank at Hadassah.

Part of the tumor is stained with hematoxylin-and-eosin and Histopathologic diagnosis is performed by a pathologist.

DNA is extracted from whole blood, serum and tumor of all patients with low grade or high grade gliomas.

In order to determine whether serum DNA represents the tumor DNA, LOH of 1p,19q,10q,17p,13q, 9p as well as methylation status of MGMT promoter will be tested in DNA samples from blood, serum and tumor.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

LOW AND HIGH GRADE GLIOMAS

Exclusion Criteria:

NON GLIAL TUMORS

Study Design

Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal


Related Conditions & MeSH terms


Locations

Country Name City State
Israel Hdassah Medical Organization Jerusalem

Sponsors (1)

Lead Sponsor Collaborator
Hadassah Medical Organization

Country where clinical trial is conducted

Israel, 

See also
  Status Clinical Trial Phase
Recruiting NCT05539677 - Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research
Recruiting NCT04066465 - Neurocognitive Function After Proton Therapy in Children and Adolescents
Completed NCT02392078 - Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
Not yet recruiting NCT02272452 - Assistance in Neurosurgery (ExtempoRMN) N/A
Recruiting NCT06104488 - A Study of Avutometinib for People With Solid Tumor Cancers Phase 1
Completed NCT02338037 - Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors Early Phase 1
Completed NCT05328739 - The Effect of Home Care Planned According to Orem in Patients With Primary Brain Tumor and Their Caregivers N/A
Completed NCT02034708 - Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors Phase 4
Terminated NCT00629395 - Computerized Cognitive Training for Childhood Cancer Survivors N/A
Completed NCT04919993 - CBT for Insomnia in Primary Brain Tumor Patients N/A
Completed NCT04075370 - Exploring Compensation to Maintain Cognitive Function in Adults Newly Diagnosed With Brain Cancer
Completed NCT01242566 - Temozolomide in Elderly Patients With KPS < 70 Phase 2
Not yet recruiting NCT06439420 - CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial Phase 2
Recruiting NCT01535430 - Assessment of Eloquent Function in Brain Tumor Patients
Completed NCT00285324 - Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis N/A
Recruiting NCT03684109 - Non-invasive Glioma Characterization Through Molecular Imaging N/A
Recruiting NCT05576103 - Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients
Recruiting NCT05106296 - Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer Phase 1
Completed NCT04118426 - Cognitive Function After Radiation Therapy for Brain Tumours
Recruiting NCT02693405 - Executive and Socio-cognitive Functions in Survivors of Primary Brain Tumor: Impact on Patients' Quality of Life N/A